Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone therapy for postmenopausal women appears safe and may protect against heart disease, but requires constant monitoring and more research for long-term effects.

Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.

Oral minoxidil may have more cardiovascular risks than topical minoxidil.

Dutasteride is as safe for the heart as finasteride.

Extra safety steps are needed for older patients and those with heart disease having hair restoration surgery.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.

Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.

Short-term testosterone therapy in women seems safe with few mild side effects, but long-term effects need more research.

Oral minoxidil improves hair growth in men with hair loss, but caution needed for those with heart issues.

Low-dose oral minoxidil is effective and safe for hair loss, but more research is needed.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Testosterone therapy can safely and effectively treat symptoms like low libido and fatigue in women, especially after menopause.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Oral minoxidil effectively promotes hair growth in men with hair loss, but caution is needed for older or heart-risk patients.

Systemic minoxidil is generally safe for older adults, but caution is needed for those with heart risks.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Oral minoxidil promotes hair growth but may cause side effects; needs monitoring.

Folate may reduce methotrexate side effects in psoriasis patients, but its impact on effectiveness is unclear.

Oral Minoxidil is a practical alternative to Topical Minoxidil for hair loss, but treatment should be personalized.

Some heart drugs show promise for other conditions, but more research is needed to confirm their effectiveness and safety.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.

Low-dose oral minoxidil is effective for treating hair loss with personalized plans and safety monitoring.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

DHEA supplementation may improve quality of life, neuropsychological functions, and sexual satisfaction in individuals with adrenal insufficiency, but more research is needed to confirm its safety and effectiveness.

Panax ginseng is generally safe with mild side effects and may have health benefits, but more research is needed.